Merck & Co., Inc. (NYSE:MRK) reported ISL/LEN combo met noninferior viral suppression at Week 48 with no new safety signals, cut royalty-free licenses for once-monthly alimatravir in 129 low-income countries, and expanded trials of Spevatamig with Keytruda plus chemo in biliary tract cancer.
Previous Week Recap
- Merck & Co., Inc. Islatravir Noninferior Week 48: Merck's islatravir (MK-8591) with Gilead's lenacapavir (ISL/LEN) showed noninferior viral suppression at Week 48 in ISLEND-1/2; 0% vs 0.3% ≥50 copies/mL in ISLEND-1; no new safety issues.
- MRK Licenses For Alimatravir To Generics: Merck (MRK) struck royalty‑free licenses with seven generics to allow manufacture and supply of once‑monthly HIV pill alimatravir in 129 low and lower‑middle‑income countries, pending approvals
- MRK Phanes Spevatamig Keytruda Collaboration: Merck (MRK) expanded a clinical collaboration with Phanes to evaluate Spevatamig plus Keytruda and chemo in biliary tract cancer, covering trial cooperation and study drug supply.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.